Herbal medicines are widely utilized for disease prevention and health promotion.
A variety of herbal products is available for treating acute bronchitis, some of which are based on combinations of various active ingredients. In particular, GHX02 is the extract composed of a mixture of FIGURE 1 Body weight (mean ± SD) of male and female rats treated with 0, 1250, 2500 and 5000 mg/kg/day in the 28-day repeated-dose oral toxicity study of GHX02 with a 14-day recovery period. * Significantly different from the vehicle control at P < .05
[Colour figure can be viewed at wileyonlinelibrary.com] roots and seeds of four herbs: Gwaruin (Trichosanthes kirilowii);
Haengin (Prunus armeniaca); Hwangryeon (Coptis japonica); and Hwangkeum (Scutellaria baicalensis). The components of GHX02 have been traditionally used to improve acute bronchitis with few side effects, as suggested by empirical evidence (Lyu et al., 2018) .
A series of studies were performed on GHX02 to produce toxicity data to support future clinical studies. Although GHX02 has been used as an herbal medicine in Korea, its toxicological data, which is essential for Investigational New Drug (IND) application, have not yet been submitted for IND review. Therefore, we evaluated the safety of GHX02 and got approval of phase II clinical trials for the treatment of acute bronchitis, multicenter-based, including dose-finding, double-blind, randomized placebo-controlled trial of two different doses of GHX02. ClinicalTrials.gov Identifier: NCT03310385.
In our studies, the safety of GHX02 was estimated by a single-dose oral toxicity study and a 28-day repeated-dose oral toxicity study using Sprague-Dawley rats with a 14-day recovery period. In addition, genotoxicity was assessed using a bacterial reverse mutation test (Ames test), in vitro chromosomal aberration test, in vivo mouse micronucleus assay and single cell gel electrophoresis assay (comet assay).
| MATERIALS AND METHODS

| Preparation of GHX02
GHX02, soft brown extract, was provided by Hankookshinyak Pharmaceutical Co., Ltd. produced using the standards of Good Manufacturing Practice. GHX02 for oral administration or treatment was formulated in sterile distilled water. The components, parts and ratio of GHX02 are described in a previous paper (Lyu et al., 2018) .
| Experimental animals and husbandry
All toxicological studies were carried out by Chemon Inc. under Good Laboratory Practice (GLP) conditions. Specific pathogen-free Sprague-Dawley rats (Crl:CD(SD)) were used for general toxicity studies and the comet assay. Specific pathogen-free ICR mice (CrljOri:CD1(ICR)) were used for the bone marrow micronucleus assay. The rats and mice used for the general toxicity and bone marrow micronucleus tests were gained from Orientbio Inc., and the rats for the comet assay were obtained from Samtako Inc. The studies were approved by the Institutional Animal Care and Use Committee (IACUC). Animals were housed in the laboratory animal facility at a temperature of 22 ± 3°C and a relative humidity of 50% ± 20%. The animal rooms were maintained under a 12-hour light-dark cycle, and 10-20 air changes per hour. Animals were supplied irradiation-sterilized pellet feed (Teklad Certified Irradiated Global 18% Protein Rodent Diet, 2918C; Envigo RMS, Inc.) along with tap water disinfected using an ultraviolet sterilizer and ultrafiltration ad libitum. All animals were acclimated for 7 days before the start of the experiment. For the single-dose oral toxicity study, the animals were housed in stainless steel cages with mesh bottom. For the repeated-dose studies and the micronucleus test, the animals were housed in a solid bottom polycarbonate cage with bedding.
| Single-dose oral toxicity study
Six-week-old Sprague-Dawley male and female rats (n = 5 per sex and group) were orally treated with GHX02 at 0 and 5000 mg/kg. Animals were housed in stainless steel cages with mesh bottoms. No more than three animals were housed per cage during the quarantine and FIGURE 2 Effect of GHX02 on the weekly food and water consumption after oral administration in male and female rats for 28 days. A, Weekly food consumption. B, Weekly water consumption. Data are expressed as the mean ± SD [Colour figure can be viewed at wileyonlinelibrary.com] acclimation period, and the animals were individually housed during the dosing and the observation period. The clinical signs and mortality were monitored constantly for the first 30 minutes, and then every hour until 6 hours after oral treatment and daily for 14 days subsequently. During the 15-day experimental period, the body weight of all group rats was recorded, and gross findings were observed at necropsy.
| 28-Day repeated-dose oral toxicity study
The 28-day repeated-dose oral toxicity study was performed according to OECD TG407. The high dose was set at 5000 mg/kg/day as GHX02 is a mixture of many compounds of unknown concentration, and there were no toxic signs in the single-dose study. Six-week old Sprague-Dawley rats (n = 10 per sex and group) were orally administered with GHX02 at 0, 625, 1250, 2500 and 5000 mg/kg/day for 28 days to male and female rats in this study. Five animals/sex were added to the vehicle control group and the high-dose group (5000 mg/kg/day) to evaluate the recovery potential. The body weight ranges at the initiation of dosing were 192.42-226.39 g for males and 150.23-175.29 g for females, respectively.
Animals were checked once a day to observe any clinical signs and mortalities, and the type, date of occurrence and severity of signs were recorded individually. The body weights of all group rats were recorded before the initiation of dosing (day 1) and once a week during the experimental period. Before necropsy, all group rats were fasted overnight and the body weight of all group rats were mean cell hemoglobin concentration, red cell distribution width, mean platelet volume (MPV), reticulocytes, white blood cell count and white blood cell count differential count (neutrophils, basophils, monocytes, lymphocytes, eosinophils and large unstained cells).
Serum biochemical parameters were measured using a serum biochemistry analyzer (AU680; Beckman Coulter). About 2 mL of the blood sample was added into a 5 mL Vacutainer tube (SST™ II Advance; BD) that contained clot activator. The blood was coagulated by remaining at room temperature for 15-20 minutes and then centrifuged for 10 minutes (3000 rpm, 1902 Relative Centrifugal Force (RCF), Combi-514R; Hanil) to collect serum sample.
The parameters examined were aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, creatine phosphokinase, reticulocytes, total bilirubin, glucose, total cholesterol, triglyceride, total protein, albumin, albumin/globulin ratio, blood urea nitrogen (BUN), creatinine, inorganic phosphorus, calcium, sodium, potassium ion and chloride ion.
After the blood sampling, animals were killed by exsanguination from the abdominal aorta and posterior vena cava. Gross findings were recorded including the body surface, subcutis, head and all organs in the abdominal and thoracic cavities. Following this, organs were weighed using an electronic balance (Sartorius AG): kidney (both), spleen, liver, thymus, heart, lung, brain and adrenal gland.
Organ weights (%) relative to the terminal body weights were also calculated. Tissue slides were prepared from fixed tissues with gross findings of all animals, and histopathological examination was performed. The histopathological findings were processed by the Pristima ® (xybion) program. The diagnostic terms in the lexicon of Pristima ® were used primarily.
| Bacterial reverse mutation test
The mutagenic potential of GHX02 was evaluated by bacterial reverse mutation assay according to OECD TG471. The four histidine auxotroph strains of Salmonella typhimurium TA100, TA1535, TA98 and TA1537 along with a tryptophan auxotroph strain of Escherichia coli, WP2 uvrA (pKM101), were used for bacterial reverse mutation testing (Green & Muriel, 1976; Maron & Ames, 1983) . The metabolic activation system consisted of the cofactor-supplemented post-mitochondrial fraction (S9) of liver homogenate from rats pretreated with phenobarbital and 5,6-benzoflavone (Claxton et al., 1987) . The test strains were exposed to the test article using the preincubation method. Based on the results of a range-finding test conducted on the test article, dose ranges were determined using the five test strains in both the presence and absence of the metabolic activation system with three plates per dose. In this study, the highest dose of this study was set at 5000 μg/plate for all test strains, and six-serial diluted concentrations (5000, 2500, 1250, 625, 313 and 0 μg/plate) were tested in the main study. The colonies were counted using an automated ProtoCOL 3 colony counter (Synbiosis).
| In vitro chromosomal aberration test
The in vitro chromosomal aberration test was performed according to OECD TG473. Chinese hamster lung cells (CHL/IU) were obtained from the American Type Culture Collection. The cells were maintained with Eagle's minimum essential medium supplied with 10% fetal bovine serum and used for chemical treatment (Koyama, Utakoji, & Ono, 1970) . The cells were cultured at 37 ± 1°C and 5% CO 2 -95% air using a humidified incubator (MCO-20AIC; Sanyo) and cell culture flasks (culture surface 75 cm 2 ). Dose ranges of this study were determined by the cytotoxicity (ascertained via relative population doubling) observed in a range-finding test. The highest dose was chosen to produce <50% relative population doubling. The cells were plated in 60 mm culture plates at a density of 2.5 × 10 5 cells/plate and incubated for approximately 24 hours before chemical treatment. The cells were treated with each dose and incubated for 24 hours. After incubation, the cells were harvested and slides were prepared (Ishidate, 1981; Sofuni, 1998) . In total, 100 metaphases per culture (200 metaphases per dose) were evaluated for chromosome aberrations.
The slides of continuous treatment series were not observed because a positive result was obtained in the short-duration treatment series.
The results are represented as the mean percentage of metaphases with structural or numerical aberrations per 200 metaphases.
| In vivo mouse bone marrow micronucleus test
The in vivo micronucleus test was performed according to OECD TG474. Five or seven male ICR mice (8 weeks old, 33.3-37.9 g) per dose were orally administered with GHX02 at doses of 1250, 2500
and 5000 mg/kg/day. The animals of the positive control group were treated with mitomycin C (Sigma-Aldrich Co.) once intraperitoneally.
Animals were killed 24 hours after the final administration. The bone marrow smears of mice were prepared and counting of micronuclei was performed according to the previous study (Schmid, 1975 A total of 150 cells were counted per animal and the median value of the percentage tail DNA was calculated (Olive, Banáth, & Durand, 1990) . 3 | RESULTS
| In vivo alkaline comet assay
| Single-dose oral toxicity study
There were no unscheduled deaths. There were no test article-related clinical signs or body weight changes. The histopathological examination was not performed, as there were no organs with a gross lesion.
Thus, the approximate lethal dosage of GHX02 was higher than 5000 mg/kg in male and female rats (Table 1) .
| 28-Day repeated-dose oral toxicity study
No GHX02-related deaths were found during the 28-day exposure period. Compound-colored stool was observed in the 5000 mg/kg/ day group in both sexes during the administration period. No significant changes were found in body weight gain, food and water intake.
In the recovery groups, the body weight was temporarily increased in the 5000 mg/kg/day group in females (P < .05) (Figure 1) . Nevertheless, the extent of the increase was minor. After the recovery period, no significant changes were found in food and water intake. No abnormalities were found in the ophthalmological examination in any animal both in the main and the recovery group (Figure 2) .
In urinalysis, the levels of ketone bodies were significantly increased in males and females at the dose of 5000 mg/kg/day (P < .05) ( Table 2 ). The significant decrease in PLT (male, in the 5000 mg/kg/day group) was not considered of toxicological significance because the changes were not accompanied by correlated findings related to MPV. The MPV of male rats was significantly lower in the 5000 mg/kg/day group during the recovery period, but there was no significant change in PLT level (Tables 3 and 4 ).
The results of serum biochemistry in comparison with the negative control are shown in Tables 5 and 6. The level of K + significantly increased in the males of the main study groups at 1250 mg/kg/day (P < .05), but the change was not associated with GHX02 as there was no dose-related response. In the recovery group, the levels of ALT and BUN significantly decreased in females in the 5000 mg/kg/day group, respectively (P < .05 and P < .01). However, these decreases were not observed in the main study groups and no differences were detected in the liver and kidney upon autopsy and histopathology assessment.
The absolute and relative weights of various organs are shown in Tables 7 and 8. The absolute weight of the left epididymis in the 5000 mg/kg/day male group significantly increased (P < .05) whereas the relative weight of the right kidney in the 1250 mg/kg/day female group significantly decreased (P < .05). In the recovery group, the absolute weight of the heart significantly increased in females in the 5000 mg/kg/day group due to an increase of fasting body weights.
The decreased relative weight of the heart was observed only in the recovery group but it was considered to fall within the normal ranges (Han et al., 2010) .
The histopathological results in male and female rats are shown in Table 9 . Based on the histopathological results, there were no abnormalities attributable to the administration of GHX02. Hydronephrosis in the kidney was observed in all male groups albeit without a doserelated response. The retention of clear fluid was observed in the female uterus of all female groups but was not attributed to GHX02; rather, this probably resulted from natural change during the estrous cycle.
| Bacterial reverse mutation test
Precipitation was seen on all test plates at 2500 and 5000 μg/plate at the time of plate scoring. There was no microbial colonization found No. of animals 10 10 10 10 5 5 due to contamination in any of the plates for the sterility check of the test article and S9 mix. There was neither an increase of revertants nor cytotoxicity in TA100, TA1535, TA98, TA1537 and WP2 uvrA (pKM101) at any dose level of the test article both in the presence and the absence of the metabolic activation system. The mean revertant of the positive control for each test strain exhibited a clear increase over the mean revertant of the negative control for that strain (Table 10 ).
| In vitro chromosomal aberration test
There was no statistically significant increase in the frequencies of (Table 11 ).
| In vivo micronucleus test
There were no unscheduled deaths or animals with any clinical signs.
The frequency of MNPCEs was not increased at all dose levels of GHX02 while mitomycin C induced a clear increase in the frequency of MNPCE (P < .01). The ratios of PCE/RBC were not significantly different at all dose levels of GHX02 (Table 12 ).
| In vivo alkaline comet assay
No statistically significant or dose-related increase was observed in the median of percentage tail DNA at all in the GHX02 administration group compared with that of the negative control group. The values were within the distribution of histological control data. The statistically significant increase was observed in the positive controls compared with the negative controls (P < .01) (Table 13 ).
| DISCUSSION
In our studies, the safety of GHX02 was estimated by single-dose oral toxicity study and a 28-day repeated-dose oral toxicity study using Sprague-Dawley rats with a 14-day recovery period. In addition, genotoxicity was assessed using a bacterial reverse mutation test (Ames test), in vitro chromosomal aberration test, in vivo mouse micronucleus assay and single cell gel electrophoresis assay (comet assay).
In the single-dose oral toxicity study, there was no GHX02-related toxicity. In the 28-day repeated-dose oral toxicity study, though there were statistically significant changes in some parameters, they were not considered adverse as they were within the normal range or showed a lack of a dose relationship, or they were not accompanied by any significant changes in the relevant parameters.
In the chromosomal aberration study, the frequency of numerical aberrations increased in all dose groups compared with the concurrent negative control. Numerical chromosome aberrations were PP and ER.
From these results, an interesting observation was the induction of ER in the presence of the S9 mix and PP in the absence of the S9 mix in a dose-dependent manner. ER is caused by successive cycles of replication without segregation of daughter chromatids and is rarely observed in animal cells. ER is usually induced by chemicals that inhibit topoisomerase II (Pastor, Cantero, Campanella, & Cortés, 2005; Sumner, 1998; Sutou & Tokuyama, 1974) . Some flavonoids (genistein, fisetin, luteolin and quercetin) are known as DNA topoisomerase inhibitors (Yamashita & Kawanishi, 2000; Salti et al., 2000; Olaharski, Mondrala, & Eastmond, 2005) . PP is defined as an exact multiple of the haploid chromosome number and is induced by inhibition of DNA topoisomerase. In this in vitro chromosome aberration test, PP is only defined as ≥37 centromeres.
The mechanisms of numerical aberration may involve topoisomerase inhibition or cytoskeleton disturbance, DNA damage, disruption of cellular checkpoint controls (Cortés, Mateos, Pastor, & Dominguez, 2004) . The increase of PP indicates that a chemical has the potential to induce numerical aberration. Although aneugens may induce PP, such an increase of PP does not indicate aneugenic potential, but rather may reflect either cell cycle perturbation or cytotoxicity. In addition, OECD TG473 is not designed to measure numerical aberrations and the guideline recommends an in vitro micronucleus test (OECD TG487) for the detection of aneuploidy.
Therefore, the increase of numerical aberrations in the in vitro study may not be directly relevant to the in vivo genetic risk. This argument may be supported by the fact that GHX02 did not result in any positive response in any of the in vivo genetic toxicity studies conducted in this project.
| CONCLUSION
The toxicity of GHX02 was evaluated by a single oral toxicity study, a 28-day repeated-oral toxicity study, in vitro and in vivo. GHX02
was not found to exhibit mutagenic or genotoxic potential. Moreover, no significant changes were observed in GHX02-treated groups compared with the vehicle control group on histopathological examination by a 28-day repeated-dose oral toxicity study. Therefore, it was concluded that GHX02 administration up to 5000 mg/kg/day yielded no adverse effects and that the noobserved-adverse-effect level was 5000 mg/kg/day in both sexes.
Furthermore, our toxicological data of GHX02 contributed to allow us to get IND and approval of phase II (ClinicalTrials.gov Identifier: NCT03310385).
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